TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Male~* Female that is highly unlikely to become pregnant~* Patient is not on an antihyperglycemic agent (AHA) (hemoglobin A1c \[A1C\] 7-10%) or on oral single AHA or low-dose combination therapy (A1C 6.5-9.0%)~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis~* Patient has required insulin therapy within the past 12 weeks~* Patient is on or has been taking a Peroxisome Proliferator-Activated Receptor-gamma (PPAR -gamma) agent (i.e. Thiazolidinediones \[TZDs\]) within the prior 12 weeks of the screening visit.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: drug
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: active comparator
- 3 (Type: EXPERIMENTAL): Arm 3: drug + active comparator
- 4 (Type: PLACEBO_COMPARATOR): Arm 4: placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to complete questionnaires by themselves or with assistance~* Planned paclitaxel at a dose of 80 mg/m2 IV given, in the adjuvant breast cancer (postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for PARP inhibitors)~* Life expectancy \> 6 months~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Negative pregnancy test (serum or urine) done =\< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion)~Exclusion Criteria:~* Any of the following:~  * Pregnant women~ * Nursing women~ * Men or women of childbearing potential who are unwilling to employ adequate contraception~* Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause~* History of allergic or other adverse reactions to minocycline~* Prior exposure to neurotoxic chemotherapy~* Diagnosis of fibromyalgia~* Current or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloids~* History of allergic or other adverse reactions to tetracycline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (minocycline hydrochloride) (Type: EXPERIMENTAL): Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Adductor Canal Versus Femoral Nerve Blocks for Anterior Cruciate Ligament Reconstruction in Pediatrics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I or II~* Age 8 to 18 years~* All research subjects must have an acceptable legally authorized representative capable of giving consent on the subject's behalf.~Exclusion Criteria:~* Those who were unable to use a standard 0-10 NS~* Infection at the site of the block~* Bleeding disorders~* Allergy to the drugs used to perform the block ( ropivacaine , methylprednisolone)~* Those who refused a nerve block or enrollment in the study.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Adductor Canal block (Type: ACTIVE_COMPARATOR): Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
- Femoral Nerve block (Type: ACTIVE_COMPARATOR): Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-45 years old~* Superficial partial thickness burns less than or equal to 10% Total Body Surface Area~Exclusion Criteria:~* Patients with burns involving the primary areas (face, hand, groin, joints, feet)~* Previous treatment of the burn wound~* Previous burn injury to the same area, electrical burn, and patients with inhalation injury~* Patients with diabetes, known sensitivity or allergy to one of the dressings or their constituents and allergy to NSAIDS~* Those being treated with systematic steroid medication~* Patients with AIDS and AIDS related complex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Open Dressings with Petrolatum Jelly (Type: EXPERIMENTAL): participants randomized to this arm had their wounds dressed with Open Dressing with Petrolatum Jelly
- Silver Sulfadiazine Gauze Dressing Group (Type: ACTIVE_COMPARATOR): Participants randomized to this arm had their wounds dressed with Silver Sulfadiazine Gauze Dressing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine 10% Spray Reduces Pain During Intrauterine Device Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Age \>18 Not pregnant Smear negative~Exclusion Criteria:~Chronic pelvic pain Pregnancy Uterine anomaly Fibroid Acute cervicitis Pelvic inflammatory disease Cervical stenosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- saline spray application (Type: PLACEBO_COMPARATOR): Placebo group
- lidocaine spray application (Type: EXPERIMENTAL): 2 puff lidocaine spray applicated before IUD insertion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kiosk-Model Self-Triage System in the Pediatric Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 0 and 18 years of age~* Registered in the Pediatric ED~* Accompanied by parent/guardian 18 years or older~* Version 3 Emergency Severity Index (ESI) of 3 to 5~* Parent or guardian able to communicate in English or Spanish~Exclusion Criteria:~* Deemed medically unstable~* ESI score of 1 or 2~* Incarcerated or in juvenile detention~* Parent/guardian unable to communicate in English or Spanish

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Self-triage kiosk (Type: EXPERIMENTAL): Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
- Nurse-initiated triage (Type: EXPERIMENTAL): Nurse-initiated triage for obtaining medical history and presenting problem(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male gender~* at least six AKs per field~Exclusion Criteria:~* history of photosensitivity related disorders~* active infectious disease,~* immunosuppression~* laser or any cosmetic treatment in the previous 6 months~* other topical agents in the treatment area such as retinoids, 5-fluorouracil,imiquimod or diclofenac sodium in the previous 3 months~* allergy to MAL or excipients of the cream~* poor patient compliance.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Conventional MAL-PDT (Type: OTHER): Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
- Calcipotriol assisted MAL-PDT (Type: OTHER): Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with asthma as determined by ICD-9 codes and asthma drug use~* at least 65 years of age~* prescription for an inhaled corticosteroid~Exclusion Criteria:~* a diagnosis of chronic obstructive pulmonary disease or~* a prescription for a chronic obstructive pulmonary disease treatment

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medicare-eligible subjects with asthma (Type: None): Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dark Chocolate, Coconut Water, and Ibuprofen in Managing Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged between 17 and 24 years~* Diagnosed with primary dysmenorrhea based on specific characteristics and assessment~* Willing to refrain from using any pharmacological or non-pharmacological therapies other than the interventions provided by the researcher~* willing to participate as respondents~Exclusion Criteria:~* Allergies to dark chocolate or young coconut water or contraindications to Ibuprofen consumption~* Diagnosed with specific gynecological conditions.

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- Ibuprofen (Type: ACTIVE_COMPARATOR): Fifteen participants were randomly selected to form the third intervention group. Each subject in this arm received a single tablet of Ibuprofen, with a dosage of 400 mg. Similar to the other arms, they were given a 15-minute window to take the Ibuprofen tablet.~Prior to administering the Ibuprofen, the pain intensity of the participants was measured using the standardized Numeric Rating Scale (NRS). Additionally, the pain intensity was measured again two hours after the consumption of the Ibuprofen tablet, using the same Numeric Rating Scale (NRS).
- Young Coconut Water (Type: ACTIVE_COMPARATOR): Fifteen participants were randomly selected to join the intervention group. Each subject in this arm received a single dose of 330 ml of young coconut water. To ensure uniformity, they were given a 15-minute window to consume the entire 330 ml of the young coconut water intervention.~Before administering the young coconut water, the pain intensity of the participants was measured using a standardized Numeric Rating Scale (NRS). Additionally, the pain intensity was reevaluated two hours after the consumption of the young coconut water, using the same Numeric Rating Scale (NRS).
- Dark Chocolate Bar (Type: ACTIVE_COMPARATOR): Fifteen participants were also randomly chosen for the second intervention group. In this arm, each subject received a single 70% dark chocolate bar weighing 35 grams. Similar to Arm 1, they were given a 15-minute timeframe to consume the entire dark chocolate bar intervention.~Prior to giving the dark chocolate bar, the pain intensity of the participants was measured using the Numeric Rating Scale (NRS). Subsequently, the pain intensity was reassessed two hours after the consumption of the dark chocolate bar, using the same Numeric Rating Scale (NRS).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 75 years of age~* Low density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and \< 190 mg/dL~* Framingham risk score of 10% or less~* Fasting triglycerides \< 400 mg/dL~Exclusion Criteria:~* History of coronary heart disease~* New York Heart Association (NYHA) II - IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
- Placebo Q4W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
- Ezetimibe (Type: ACTIVE_COMPARATOR): Participants received 10 mg ezetimibe orally once a day for 12 weeks.
- Evolocumab 70 mg Q2W (Type: EXPERIMENTAL): Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 105 mg Q2W (Type: EXPERIMENTAL): Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 140 mg Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 280 mg Q4W (Type: EXPERIMENTAL): Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 350 mg Q4W (Type: EXPERIMENTAL): Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg Q4W (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CKD patients (defined as serum creatinine 1.5 to 6.0 mg/dL for women and 2.0 to 6.0 g/mg/dL for men)~* Stable Hb (\>= 11.0g/dL) and currently receiving PROCRIT therapy for 2 months or more. A stable Hemoglobin will be defined as a value that is ± 10% for 3 consecutive laboratory values.~Exclusion Criteria:~* Lactating or pregnant women~* Uncontrolled hypertension~* Known hypersensitivity to mammalian cell-derived products and human albumin~* Receiving dialysis or scheduled to receive dialysis during the course of the study~* gastrointestinal bleeding~* Severe Congestive Heart Failure (New York Heart Association Class IV)~* Concurrent chemotherapy for cancer~* History of/or active blood disorders, liver diseases or seizures~* HIV positive~* Received a kidney transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAX 855 Dose-Escalation Safety Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is male and is 18 to 65 years of age at the time of screening~* The subject has severe hemophilia A (factor VIII level \< 1%)~* The subject was previously treated with plasma-derived factor VIII (FVIII) concentrates or recombinant FVIII for at least 150 exposure days (EDs)~Exclusion Criteria:~* The subject has a detectable FVIII inhibitor at screening, with a titer \>= 0.6 BU~* The subject has a documented history of FVIII inhibitors with a titer \>= 0.4 BU at any time prior to screening~* The subject has a known hypersensitivity towards mouse or hamster proteins or to polyethylene glycol (PEG)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Low dose of ADVATE followed by low dose of BAX 855
- Cohort 2 (Type: EXPERIMENTAL): High dose of ADVATE followed by high dose of BAX 855

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Duloxetine in Psychological Resilience

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ages 18-65~* primary diagnosis of MDD based on Diagnostic Standard Manual(DSM-IV) criteria and assessed by the MINI International Neuropsychiatric Interview~* Montgomery-Asberg Depression Rating Scale (MADRS)score of at least 20 on baseline~* Minimum Clinical Global Impressions of Severity (CGS) severity score of 4~* Ability to provide written consent form~* A negative serum pregnancy test for women of childbearing potential~Exclusion Criteria:~* Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder or cognitive disorder due to a general medical condition~* History of substance abuse or dependence within the last 6 months~* Suicide risk or serious suicide attempt within the last year~* Clinically significant medical condition or laboratory abnormality~* Women of childbearing potential who are unwilling to practice an acceptable method of contraception~* Subjects needing concurrent use of psychotropic medications~* History of sensitivity to duloxetine~* History of failure to respond to an adequate trial of duloxetine (at least 60mg/day for 4 weeks)~* Subjects taking monoamine oxidase inhibitors (MAOIs)~* Subjects with uncontrolled narrow-angle glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of non-erosive form of Gastroesophageal Reflux disease~* Dietary fiber deficiency by dietary questionnaire~* pathological gastroesophageal reflux by 24-hours esophageal pH-impedance examination~* willingness to participate (signed informed consent)~Exclusion Criteria:~* presence of esophageal mucosal damages (esophagitis) by endoscopic evaluation~* gastrointestinal surgery in anamnesis~* current pregnancy or breast-feeding~* known hypersensitivity to Mucofalk or its components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mucofalk (Type: EXPERIMENTAL): Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete